Patent ID: 11912761
Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 5:
6. A method of inhibiting overexpression of IL-1β in a subject in need thereof, comprising administering to the subject an effective amount of an isolated monoclonal antibody which specifically binds to IL-1β, or an antigen binding fragment thereof, wherein said antibody or fragment thereof comprises the following Complementarity Determining Regions (CDRs):
(i) a heavy chain variable region CDR H1 comprising the amino acid sequence set forth in SEQ ID NO: 26,
(ii) heavy chain variable region CDR H2 comprising the amino acid sequence set forth in SEQ ID NO: 27,
(iii) a heavy chain variable region CDR H3 comprising the amino acid sequence set forth in SEQ ID NO: 28,
(iv) a light chain variable region CDR L1 comprising the amino acid sequence set forth in SEQ ID NO: 29,
(v) a light chain variable region CDR L2 comprising the amino acid sequence set forth in SEQ ID NO: 30, and
(vi) a light chain variable region CDR L3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 12, SEQ ID NO: 11, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 13,, wherein the subject has an autoimmune disease.